Notice of Results & Investor Presentation (1411893)

Arix Bioscience PLC (ARIX) Notice of Results & Investor Presentation 03-Aug-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Notice of Results & Investor Presentation

LONDON, 3 August 2022: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the six months ended 30 June 2022 on Wednesday 10 August 2022.

Analyst Briefing: 9:00am, Wednesday 10 August

Management will host a virtual analyst presentation followed by a Q&A session at 9:00am BST on Wednesday 10 August. Analysts wishing to join should register their interest by contacting [e-mail].

Investor Presentation: 2:00pm, Wednesday 10 August

Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2:00pm BST on Wednesday 10 August.

The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Wednesday 10 August or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/ arix-bioscience-plc/register-investor

Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

[phone]

[e-mail]

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

-----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  NOR 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   178861 
EQS News ID:    1411893 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1411893&application_name=news

(END) Dow Jones Newswires

August 03, 2022 02:00 ET (06:00 GMT)